AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04308889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Subjects will have blood drawn from the antecubital vein for not more than 15mL at each visit.
Study NCT04308889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy
Description: Subjects will have blood drawn from the antecubital vein for not more than 15mL at each visit.
Study NCT03237091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unihemispheric transcranial pulsed current stimulation (tPCS)
Description: One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
Study NCT03237091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bihemispheric transcranial direct current stimulation (tDCS)
Description: Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
Study NCT03875170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility. The subject will be asked to perform an isometric contraction, with a series of 3 seconds for sustained contraction and a rest between contraction of 2 to 3 seconds after activating the Golgi apparatus, making an inhibition of the stimulus and bringing the joint and muscle to the highest possible range of motion without pain.
Study NCT03875170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The active stretching technique will be performed for the hip, quadriceps and hamstring flexors with a voluntary antagonist activation to relax the agonist muscle, holding the movement to be performed for 30 seconds to stimulate the neuromuscular spindle and produce a relaxation of the muscle fibers.
Study NCT04161638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma Video Exposure
Description: The participants watched a 10 minute video on a computer screen that consisted of brief clips from popular television shows that depicted women with overweight and obesity and evoked negative weight-based stereotypes (e.g., clumsy, loud, and lazy). Both the high blood pressure and normal blood pressure arms participated in this intervention.
Study NCT04161638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral video exposure
Description: The participants watched a 10 minute video on a computer screen that consisted of a series of clips depicting neutral scenes (e.g., insurance commercials). Both the high blood pressure and normal blood pressure arms participated in this intervention.
Study NCT05076721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: The participants in the simulation group will receive simulation training with high-fidelity manikin to practice and implement one-hour bundle sepsis
Study NCT04203173 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session.
Study NCT00840463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambrisentan
Description: Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
Study NCT00840463 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study NCT04622852 — intervention group
Intervention type: DEVICE
Intervention: Open reduction internal fixation (ORIF) with an angular stable plate
Description: Operative treatment of proximal humeral fracture
Study NCT03590457 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Airvo 2; High-Flow nasal cannula system
Description: Noninvasive device used to deliver humidified oxygen at high flow rates up to 60 liters per minute
Study NCT03237091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unihemispheric transcranial direct current stimulation (tDCS)
Description: One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
Study NCT03237091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham-control
Description: Sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply stimulation to the scalp via the sponges for 1-2 minutes. The stimulator will then be turned off.
Study NCT03506126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leucine
Description: There are 8 different leucine test levels ranging from 20 to 120 mg of leucine per kilogram body weight per day (20-120 mg/kg/d)
Study NCT01138163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus bavituximab or placebo
Description: Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.
Study NCT02580552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobomarsen
Study NCT01138163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel plus bavituximab or placebo
Description: Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.
Study NCT03409302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALGEApp (Brief iACT intervention)
Description: Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The i-ACT intervention participants will be encouraged to login the website platform with their credentials and to complete 4 weekly sessions (1 session per week) which lasts about 1 hour each. Participants will be guided by a 3D- animated Avatar who adopts the role of a facilitator.
Study NCT03409302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control group
Description: Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The active control group will have access, through the same platform. only to limited online psycho-educational information regarding pain. Active control group will complete pre-treatment and post-treatment questionnaires in parallel with the intervention group.
Study NCT01649492 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pineapple juice (Carrefour n°1) 500 ml/day 5 days
Study NCT00934895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study
Study NCT00934895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abraxane
Description: Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
Study NCT00605319 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Toviaz (Fesoterodine)
Description: 4mg to 8mg by mouth once daily
Study NCT01508299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin test
Description: skin test with the Suspected raw food
Study NCT03414879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: While in the semi-setting position, patients will receive nebulization with ketamine 3 mg/kg to be completed with normal saline solution to reach a volume of 6 ml (K group; n=30) for 15 minutes before commencing the awake fiberoptic intubation..
Study NCT03414879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: While in the semi-setting position, patients will receive nebulization with lidocaine 4% 6 ml (L group; n=30) for 15 minutes before commencing the awake fiberoptic intubation
Study NCT03410147 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 13C-octanoate breath test for gastric emptying
Description: The 13C-octanoate breath test for gastric emptying will be performed to assess gastric emptying rate of a liquid meal that is infused continuously over a period of 8 hour.~13C-labeled sodium octanoate (food adjective) is mixed with liquid nutrients used for enteral feeding. The concentration of 13C-labeled sodium octanoate is according to the randomized treatment order. This mixture is infused at 20 ml/h for 8 hours (hourly dose of 13C-octanoate differs between treatment arms). In order to estimate gastric emptying rate quantitatively throughout the infusion period, the appearance of 13CO2 in the breath, relative to 12CO2, will be monitored by sampling the exhaled breath at a 15 minute interval.~The aim is to induce a steady state hourly 13C-recovery. This would allow to implement the prolonged breath test protocol in future clinical investigations.
Study NCT01195025 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: acetated Ringers
Description: Infusion of Ringer acetate 20 ml/kg over 30 min
Study NCT04041518 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autotransplantation
Description: Autotransplantation of tooth with an almost fully or completely developed root with intraoperative extraoral apicoectomy.
Study NCT02663167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioral Therapy
Description: The treatment consists of a standard cognitive behavioral therapy for obsessive-compulsive disorder. The treatment is delivered through an Internet platform. The child and his/her parent(s) work through the treatment with regular therapist contact several times per week.
Study NCT00745160 — intervention group
Intervention type: OTHER
Intervention: blood sample and questionnaire
Description: After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
Study NCT01195025 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: colloid
Description: Infusion of starch 10 ml/kg over 30 min
Study NCT04631978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive ophthalmologic examination
Description: Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
Study NCT01195025 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: colloid+acetated Ringer
Description: Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
Study NCT04354571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: An ultrasound-guided Erector spinae plane block was performed with the patient lying on the his side and the surgical side on the top. After skin disinfection, sterile draping was be placed and the ultrasound probe was sheathed. The level of the block was the transverse process of L2. The block was performed using a 9-12 MHz linear probe (LOGIQe, GE Healthcare, USA), which was placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) was identified, and a 22 G, 50 mm insulated needle (Sonoplex Stim, Pajunk, Germany) was inserted cranio-caudally in plane between the transverse process and the fascia of the ESM. After negative aspiration, 0.3 ml/kg of 0.25% bupivacaine was injected to confirm the correct position by visualizing the solution lifting the ESM off the transverse process.
Study NCT04354571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: caudal block was performed using anatomical landmarks and ultrasound guided and confirmed with a concentration of bupivacaine of 0.25%.
Study NCT02606539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total abdominal hysterectomy and methotrexate
Description: After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)
Study NCT02606539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate plus folinic acid alone
Description: methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
Study NCT01195025 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive hemoglobin with pulse-oximeter (SpHb)
Description: Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.
Study NCT02393092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Violence Awareness
Description: The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.
Study NCT02393092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Violence Prevention
Description: The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.
Study NCT02393092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emerging Leaders: East End curriculum
Description: The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
Study NCT02748369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: Somatostatin infusion to create a low insulin state.
Study NCT02748369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon infusion in the setting of ongoing somatostatin.
Study NCT03319628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upifitamab rilsodotin
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536
Study NCT03394547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allay
Description: pulsed shortwave therapy treatment for painful periods
Study NCT03394547 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo device is given which is identical to the Allay device but emits no pulsed shortwave therapy.
Study NCT00003659 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Filgrastim (300 μg for patients ≤ 70 kg or 480 μg for patients > 70 kg) will be administered beginning two days after each cyclophosphamide dose and given for a total of eight subcutaneous daily doses.
Study NCT00003659 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Approximately four weeks after the completion of the last cyclophosphamide dose, patients will receive rituximab 375mg/m2 as an intravenous infusion once weekly for four doses.
Study NCT00003659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide 3000mg/m2 will be given intravenously q 2 - 3 weeks x 3 doses.
Study NCT00003659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine will be administered intravenously at a dose of 25 mg/m2 per day x 5 days every 4 weeks.
Study NCT01857934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given intravenously (IV)
Study NCT01857934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Given IV
Study NCT01857934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18K322A
Description: Given IV
Study NCT01857934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell harvest
Description: Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.
Study NCT01857934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection
Description: The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.
Study NCT04585685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: A 12-session cognitive behavioral therapy for posttraumatic stress disorder
Study NCT05076721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case-based discussion training
Description: The participants in the conventional group will only do a case-based discussion in implementing one-hour bundle sepsis
Study NCT04585685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Therapy
Description: A 6-session mindfulness based therapy for posttraumatic stress disorder aimed at enhancing self-compassion
Study NCT03751735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton Jelly Mesenchymal stem cells
Description: Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
Study NCT04677270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital problem solving tool
Description: Digital problem solving tool - adapted for practical and emotional problems during the COVID-19 pandemic
Study NCT00473694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Administered as an intravenous (IV) infusion
Study NCT01546129 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Dianatal Obstetric Gel (Cross-linked polyacrylic acid)
Description: Dianatal (approx. 30 mL in total) will be intermittently administered to the birth canal after vaginal examination in labor using the Dianatal applicator or the syringe or the fingers. Dianatal Stage I is used during labor stage I, Dianatal Stage 2 is used during stage 2. After rupture of the membranes supplementary Dianatal is applied within 5 to 20 minutes.
Study NCT00473694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: Administered as an IV infusion
Study NCT00473694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vecuronium
Description: Administered as an IV infusion
Study NCT00473694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vecuronium
Description: Administered as an IV infusion
Study NCT00473694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: Administered as an IV infusion
Study NCT00473694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: Administered as an IV infusion